Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy

被引：7
|
作者：
Breccia, Massimo
Cannella, Laura
Nanni, Mauro
Stefanizzi, Caterina
Alimena, Giuliana
机构：
[1] Univ Roma La Sapienza, Dept Human Biotechnol & Hematol, IT-00161 Rome, Italy
[2] Univ Roma La Sapienza, Dept Cell Biotechnol & Hematol, Rome, Italy
来源：
ACTA HAEMATOLOGICA | 2007年 / 118卷 / 03期
关键词：
D O I：
10.1159/000108639
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：162 / 164
页数：3
相关论文
共 50 条
  • [1] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Guoqing Wei
    Shamudheen Rafiyath
    Delong Liu
    Journal of Hematology & Oncology, 3
  • [2] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Wei, Guoqing
    Rafiyath, Shamudheen
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
  • [3] Nilotinib and Dasatinib in the First-Line Therapy for chronic myeloid Leukemia
    Pretscher, Dominik
    Wilhelm, Martin
    MEDIZINISCHE KLINIK, 2010, 105 (08) : 588 - 588
  • [4] Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib
    Quintas-Cardama, Alfonso
    Jabbour, Elias J.
    LEUKEMIA RESEARCH, 2013, 37 (05) : 487 - 495
  • [5] Nilotinib as first-line therapy for chronic myeloid leukemia
    Vaid, A.
    INDIAN JOURNAL OF CANCER, 2011, 48 (04) : 438 - 445
  • [6] Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study
    Giles, Francis J.
    Rosti, Gianantonio
    Beris, Photis
    Clark, Richard E.
    le Coutre, Philipp
    Mahon, Francois-Xavier
    Steegmann, Juan-Luis
    Valent, Peter
    Saglio, Giuseppe
    EXPERT REVIEW OF HEMATOLOGY, 2010, 3 (06) : 665 - 673
  • [7] Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
    Swords, Ronan
    Mahalingam, Devalingam
    Padmanabhan, Swaminathan
    Carew, Jennifer
    Giles, Francis
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2009, 3 : 89 - 101
  • [8] Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China
    Na Li
    Bin Zheng
    Hong-Fu Cai
    Jing Yang
    Xiao-Feng Luo
    Li-Zhu Weng
    Feng-Mei Zhan
    Mao-Bai Liu
    Clinical Drug Investigation, 2018, 38 : 79 - 86
  • [9] Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China
    Li, Na
    Zheng, Bin
    Cai, Hong-Fu
    Yang, Jing
    Luo, Xiao-Feng
    Weng, Li-Zhu
    Zhan, Feng-Mei
    Liu, Mao-Bai
    CLINICAL DRUG INVESTIGATION, 2018, 38 (01) : 79 - 86
  • [10] Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012
    Romero, Martin
    Chavez, Diana
    De los Rios, Magali
    Alvis-Guzman, Nelson
    BIOMEDICA, 2014, 34 (01): : 48 - 59
12345